<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Rusiecka OM</dc:creator>
  <dc:creator>Montgomery J</dc:creator>
  <dc:creator>Morel S</dc:creator>
  <dc:creator>Batista-Almeida D</dc:creator>
  <dc:creator>Van Campenhout R</dc:creator>
  <dc:creator>Vinken M</dc:creator>
  <dc:creator>Girao H</dc:creator>
  <dc:creator>Kwak BR</dc:creator>
  <dc:date>2020</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Since the mid-20th century, ischemic heart disease has been the world's leading cause of death. Developing effective clinical cardioprotection strategies would make a significant impact in improving both quality of life and longevity in the worldwide population. Both ex vivo and in vivo animal models of cardiac ischemia/reperfusion (I/R) injury are robustly used in research. Connexin43 (Cx43), the predominant gap junction channel-forming protein in cardiomyocytes, has emerged as a cardioprotective target. Cx43 posttranslational modifications as well as cellular distribution are altered during cardiac reperfusion injury, inducing phosphorylation states and localization detrimental to maintaining intercellular communication and cardiac conduction. Pre- (before ischemia) and post- (after ischemia but before reperfusion) conditioning can abrogate this injury process, preserving Cx43 and reducing cell death. Pre-/post-conditioning has been shown to largely rely on the presence of Cx43, including mitochondrial Cx43, which is implicated to play a major role in pre-conditioning. Posttranslational modifications of Cx43 after injury alter the protein interactome, inducing negative protein cascades and altering protein trafficking, which then causes further damage post-I/R injury. Recently, several peptides based on the Cx43 sequence have been found to successfully diminish cardiac injury in pre-clinical studies.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/100570</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/biom10091225</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32842488</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Biomolecules. - 2020</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Cx43</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">cardioprotection</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">connexin</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">gap junction</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">hemi-channel</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">ischemia/reperfusion injury</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">myocardial infarction</dc:subject>
  <dc:title xmlns:ns8="xml" ns8:lang="en">Canonical and Non-Canonical Roles of Connexin43 in Cardioprotection.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
